$CSTL

Castle Biosciences (CSTL) will present data on its DecisionDx-Melanoma test at two medical conferences. Studies linked test results to survival outcomes, showing significant differences in survival rates based on risk classifications. The test has been ordered over 260,000 times since launch.

Castle Biosciences presented data on DecisionDx-Melanoma at SDPA and Dermato-Onco2026, showing the test can identify higher-risk patients with thin melanomas and provide individualized five-year recurrence-risk estimates. The studies suggest the test refines risk assessment beyond AJCC staging, aiding personalized care. According to the company, the test has been ordered over 260,000 times and is supported by extensive research.

Baird kept Castle Biosciences' rating at Outperform, lifting its price target to $41 from $39, a 5.1% increase. This implies 26.1% upside from the Nov 6 close of $32.52.

Castle Bio (CSTL) reported Q3 2026 revenue of $102.9M, up 24% YoY, driven by 47% growth in TissueCypher test volume. Net cash from operations was $19.7M, with $278M in cash and equivalents. The company raised full-year revenue guidance to $385M-$395M, up from $365M-$375M. DecisionDx-Melanoma saw 5% YoY growth, while TissueCypher is expected to grow 50%-52% for the year.

Castle Biosciences reported Q3 2026 revenue of $102.9M, up 24% YoY. TissueCypher test volume rose 47% YoY. The company raised full-year 2026 revenue guidance to $385-395M. Q3 net loss was $4.1M, with Adjusted EBITDA of $12.7M. The company presented new data on its DecisionDx-Melanoma test at EADV Congress 2026.

Castle Biosciences presented data on its Barrett’s esophagus test at the American College of Gastroenterology 2026 meeting. The studies showed the test's ability to predict disease progression and influence treatment decisions. According to the company, the test classified 83% of patients as low risk, differing from traditional methods. The data was presented in three studies, including two case reports and one multi-center study.

Castle Biosciences presented data at EADV 2026 showing DecisionDx-Melanoma's ability to predict low SLN positivity and high recurrence risk in melanoma patients. The study involved 2,799 patients across 29 U.S. centers, with low-risk patients avoiding SLNB showing 99.6% five-year RFS. The test also stratified recurrence risk in early-stage, transected melanomas, supporting tailored surveillance. Castle Biosciences is a Nasdaq-listed company (CSTL).

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

Castle Biosciences (CSTL) announced a study published in the Journal of the American Academy of Dermatology validating its DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma. The test integrates molecular data with clinicopathologic risk factors, demonstrating a 97.3% negative predictive value for low-risk patients and identifying those likely to benefit from adjuvant radiation therapy. The study involved 572 patients and showed the test's ability to stratify metastatic and loca

SciBase (private) received an additional order from Castle Biosciences (CSTL) for their ongoing collaboration on atopic dermatitis studies. Deliveries are expected to start in Q4 2026. The order accelerates the initial study and prepares for a second one. SciBase's CEO, Pia Renaudin, expressed excitement about the collaboration's progress.